546 related articles for article (PubMed ID: 26058465)
21. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
[TBL] [Abstract][Full Text] [Related]
22. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.
Guo YF; Pan JX; Zhuang WH
Infect Agent Cancer; 2018; 13():40. PubMed ID: 30559832
[TBL] [Abstract][Full Text] [Related]
23. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome.
Mikulska M; Nicolini L; Signori A; Rivoli G; Del Bono V; Raiola AM; Di Grazia C; Dominietto A; Varaldo R; Ghiso A; Bacigalupo A; Viscoli C
Clin Microbiol Infect; 2014 Oct; 20(10):O694-701. PubMed ID: 24575948
[TBL] [Abstract][Full Text] [Related]
27. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
28. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China.
Lei M; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG
World J Gastroenterol; 2018 Dec; 24(48):5525-5536. PubMed ID: 30622380
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
30. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
[TBL] [Abstract][Full Text] [Related]
31. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma.
Al-Mansour MM; Alghamdi SA; Alsubaie MA; Alesa AA; Khan MA
Infect Agent Cancer; 2018; 13():18. PubMed ID: 29977329
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
33. Antiviral therapies for managing viral hepatitis in lymphoma patients.
Merli M; Rattotti S; Gotti M; Arcaini L
Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702
[TBL] [Abstract][Full Text] [Related]
34. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Huang YH; He XH; Qin Y; Yang S; Lü Z; Dong M; Zhou SY; Liu P; Zhang CG; Yang JL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):385-9. PubMed ID: 22883463
[TBL] [Abstract][Full Text] [Related]
35. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
[TBL] [Abstract][Full Text] [Related]
36. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
38. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
39. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
40. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.
Jun CH; Kim BS; Oak CY; Lee DH; Cho E; Cho SB; Choi SK; Park CH; Joo YE; Lee JJ; Kim HJ
Hepatol Int; 2017 Jan; 11(1):87-95. PubMed ID: 27351765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
